Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Price above all key MAs — strong uptrend
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,692.7 Cr | ₹1,637.3 Cr | ₹1,710.7 Cr | ₹1,876.3 Cr |
| Net Profit | ₹138.4 Cr | ₹156.9 Cr | ₹154.4 Cr | ₹133 Cr |
| EPS | ₹7.01 | — | ₹7.85 | ₹6.76 |
| Operating Profit | ₹270.1 Cr | ₹285.5 Cr | ₹287.4 Cr | ₹264.9 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Alembic Pharmaceuticals Limited | ₹837.40 | +2.51% | 23.9 | ₹16.46K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 29 Jul 2025 | Dividend - Rs 11 Per Share | DIVIDEND |
| 15 Jul 2024 | Dividend - Rs 11 Per Share | DIVIDEND |
| 28 Jul 2023 | Dividend - Rs 8 Per Share | DIVIDEND |
| 17 Aug 2022 | Interim Dividend - Rs 10 Per Share | INTERIM_DIVIDEND |
| 19 Jul 2021 | Annual General Meeting/Dividend - Rs 14 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for APLLTD
View All
Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel
Alembic Pharmaceuticals has secured final USFDA approval for its generic Dapsone gel, a topical treatment for acne vulgaris. This approval, for the 5% strength, means the company can now market its version, which is therapeutically equivalent to Almirall's Aczone Gel. This development marks a significant step for Alembic in the US market, offering a new option for acne sufferers.
Alembic Pharma rises after receiving USFDA approval for Dapsone Gel, 5%
Alembic Pharmaceuticals rose 1.89% to Rs 786.05 after the company said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Dapsone Gel, 5%.
Alembic Pharmaceuticals receives USFDA final approval for Dapsone Gel
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapsone Gel, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Aczone Gel, 5%, of Almirall, LLC.